Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 380 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Children's Oncology Group Clear all
Completed Phase 2 Interventional

Gemcitabine in Treating Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

NCT00006462
View directory record Official record
Conditions
Leukemia
Interventions
gemcitabine hydrochloride
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
197
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 149 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2014 · Synced Jul 23, 2026, 10:14 AM EDT
Completed Phase 2 Interventional

Etoposide Plus Radiation Therapy Followed by Combination Chemotherapy in Treating Children With Newly Diagnosed Advanced Medulloblastoma

NCT00003573
View directory record Official record
Conditions
Brain Tumors, Central Nervous System Tumors
Interventions
filgrastim, cisplatin, cyclophosphamide, etoposide, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 21 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2008
U.S. locations
94
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Jul 23, 2026, 10:14 AM EDT
Completed Phase 1 Interventional Results available

Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas

NCT02323880
View directory record Official record
Conditions
Malignant Glioma, Recurrent Brain Neoplasm, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Glioblastoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm, WHO Grade 3 Glioma
Interventions
Pharmacological Study, Selinexor
Other · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 21 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Jul 23, 2026, 10:14 AM EDT
Completed Phase 3 Interventional

Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant

NCT00305851
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Music Therapy, Psychosocial Assessment and Care, Quality-of-Life Assessment
Procedure · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
11 Years to 24 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Jul 23, 2026, 10:14 AM EDT
Recruiting Phase 1 Interventional

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

NCT06894979
View directory record Official record
Conditions
Childhood Astrocytoma, Childhood Diffuse Intrinsic Pontine Glioma, Childhood Diffuse Midline Glioma, Childhood Glioblastoma, Childhood Malignant Glioma
Interventions
ATM Kinase Inhibitor AZD1390, Biospecimen Collection, Magnetic Resonance Imaging, Radiation Therapy, Survey Administration
Drug · Procedure · Radiation + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 22 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 23, 2026, 10:14 AM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma

NCT00554788
View directory record Official record
Conditions
Extraocular Retinoblastoma
Interventions
Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin, Cyclophosphamide, Etoposide, Filgrastim, In Vitro-Treated Peripheral Blood Stem Cell Transplantation, Radiation Therapy, Thiotepa, Vincristine Sulfate
Procedure · Drug · Biological + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 10 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2024
U.S. locations
66
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2025 · Synced Jul 23, 2026, 10:14 AM EDT
Completed No phase listed Observational

Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT01146210
View directory record Official record
Conditions
Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Minimally Differentiated Myeloid Leukemia (M0), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myelomonocytic Leukemia (M4), Childhood Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Fanconi Anemia, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Ringed Sideroblasts, Secondary Myelodysplastic Syndromes, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Monrovia, California
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Jul 23, 2026, 10:14 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Followed by Surgery and/or Radiation Therapy in Treating Young Patients With Advanced Neuroblastoma

NCT00002740
View directory record Official record
Conditions
Neuroblastoma
Interventions
filgrastim, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, mesna, vincristine sulfate, conventional surgery, peripheral blood stem cell transplantation, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2005
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Jul 23, 2026, 10:14 AM EDT
Active, not recruiting No phase listed Observational

Enrollment on the Childhood Cancer Research Network (CCRN) of the Children's Oncology Group

NCT01117168
View directory record Official record
Conditions
Pediatric Cancer, Leukemia, Sarcoma, Brain Tumors
Interventions
Not listed
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
57,816 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2030
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Jul 23, 2026, 10:14 AM EDT
Recruiting Phase 2 Interventional

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

NCT04684368
View directory record Official record
Conditions
Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma, Immature Teratoma, Malignant Teratoma, Mixed Germ Cell Tumor, Pineal Region Germ Cell Tumor, Pineal Region Immature Teratoma, Pineal Region Yolk Sac Tumor, Suprasellar Germ Cell Tumor
Interventions
Biospecimen Collection, Carboplatin, Etoposide, Filgrastim, Ifosfamide, Magnetic Resonance Imaging, Mesna, Pegfilgrastim, Peripheral Blood Stem Cell Transplantation, Questionnaire Administration, Radiation Therapy, Second-Look Surgery, Thiotepa
Procedure · Drug · Biological + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 29 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
149
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 119 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 23, 2026, 10:14 AM EDT
Completed No phase listed Observational

Biomarker Differences in Samples From Patients With Undifferentiated Sarcomas

NCT01802125
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Monrovia, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Jul 23, 2026, 10:14 AM EDT
Completed Phase 3 Interventional Results available

Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant

NCT01503515
View directory record Official record
Conditions
Fungal Infection, Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Caspofungin Acetate, Fluconazole, Laboratory Biomarker Analysis, Voriconazole
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Months to 20 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
46
States / cities
Phoenix, Arizona • Loma Linda, California • Oakland, California + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Jul 23, 2026, 10:14 AM EDT
Completed No phase listed Observational

DNA Biomarkers in Tissue Samples From Patients With Osteosarcoma

NCT01190943
View directory record Official record
Conditions
Localized Osteosarcoma, Metastatic Osteosarcoma, Recurrent Osteosarcoma
Interventions
Laboratory Biomarker Analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced Jul 23, 2026, 10:14 AM EDT
Active, not recruiting No phase listed Observational

Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

NCT00736749
View directory record Official record
Conditions
Hematopoietic Cell Transplantation Recipient, Leukemia, Solid Tumor
Interventions
Assessment of Therapy Complications, Questionnaire Administration
Procedure · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
163
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 124 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jul 23, 2026, 10:14 AM EDT
Completed No phase listed Observational

Risk-Group Classification of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT00482352
View directory record Official record
Conditions
Untreated Adult Acute Lymphoblastic Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 30 Years
Enrollment
11,196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2023
U.S. locations
176
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 141 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Jul 23, 2026, 10:14 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer

NCT00002611
View directory record Official record
Conditions
Kidney Cancer
Interventions
dactinomycin, filgrastim, cyclophosphamide, doxorubicin hydrochloride, etoposide, vincristine sulfate, conventional surgery, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
0 Years to 15 Years
Enrollment
3,031 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2003
U.S. locations
206
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Jul 23, 2026, 10:14 AM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

NCT01231906
View directory record Official record
Conditions
Localized Extraskeletal Ewing Sarcoma, Peripheral Primitive Neuroectodermal Tumor of Bone, Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
Interventions
Cyclophosphamide, Dexrazoxane, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Laboratory Biomarker Analysis, Topotecan Hydrochloride, Vincristine Sulfate
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 50 Years
Enrollment
642 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
215
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 149 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jul 23, 2026, 10:14 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma

NCT00003935
View directory record Official record
Conditions
Brain Tumors, Central Nervous System Tumors
Interventions
etoposide, vincristine sulfate, radiation therapy
Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 21 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
97
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2014 · Synced Jul 23, 2026, 10:14 AM EDT
Completed Phase 2 Interventional Results available

Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors

NCT00070109
View directory record Official record
Conditions
Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma, Peripheral Primitive Neuroectodermal Tumor
Interventions
trabectedin, pharmacological study
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 50 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
11
States / cities
Little Rock, Arkansas • Madera, California • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Jul 23, 2026, 10:14 AM EDT
Completed No phase listed Observational

Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors

NCT03206450
View directory record Official record
Conditions
Osteosarcoma
Interventions
Biospecimen Collection, Laboratory Biomarker Analysis, Questionnaire Administration
Procedure · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
18 Years to 50 Years · Male only
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
93
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2024 · Synced Jul 23, 2026, 10:14 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy Followed by Second-Look Surgery and Radiation Therapy in Treating Children With Nonmetastatic Medulloblastoma or Primitive Neuroectodermal Tumor

NCT00006461
View directory record Official record
Conditions
Untreated Childhood Medulloblastoma, Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions
cisplatin, cyclophosphamide, vincristine sulfate, etoposide, therapeutic conventional surgery, 3-dimensional conformal radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 3 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2013 · Synced Jul 23, 2026, 10:14 AM EDT
Completed Phase 1 Interventional Results available

This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas

NCT02171260
View directory record Official record
Conditions
Pediatrics, Solid Tumors
Interventions
Eribulin Mesylate
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
6 Months to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
18
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Jul 23, 2026, 10:14 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor

NCT04939597
View directory record Official record
Conditions
Central Nervous System Carcinoma
Interventions
Biospecimen Collection, Cognitive Assessment, Magnetic Resonance Imaging, Memantine Hydrochloride, Placebo Administration, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
4 Years to 17 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
137
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 110 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 23, 2026, 10:14 AM EDT
Completed Phase 2 Interventional

Irinotecan in Treating Children With Refractory Solid Tumors

NCT00004078
View directory record Official record
Conditions
Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood Infratentorial Ependymoma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
irinotecan hydrochloride
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jun 13, 2013 · Synced Jul 23, 2026, 10:14 AM EDT